Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK008 phase III trial of haploidentical HCT with or without HSV-Tk donor lymphocyte add-back in high-risk acute leukemia
NL-OMON35966Phase 3Withdrawn
- Sponsor
- MolMed
- Start
- Jul 2011
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nalotimagene carmaleucel in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), sponsored by MolMed. Planned start Jul 2011; status: withdrawn.
02
Drugs
nalotimagene carmaleucel
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON35966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35966.